```html

Keratitis Sicca (Ocular Surface Disease) – A Patient‑Friendly Guide

Overview

Keratitis sicca, also called dry‑eye associated keratitis, is an inflammation of the cornea that occurs when the ocular surface does not receive enough lubricating tears. It is a major component of the broader condition known as **dry eye disease (DED)** or **ocular surface disease (OSD)**. The lack of adequate tear film leads to epithelial damage, discomfort, and, if untreated, vision‑threatening complications.

Who it affects

• Women are 2–3 times more likely than men to develop dry‑eye‑related keratitis.
• Prevalence rises sharply after age 50; about 15 % of adults over 65 have clinically significant keratitis sicca.<sup>[1]</sup>
• People with autoimmune diseases (e.g., Sjögren’s syndrome, rheumatoid arthritis) have a markedly higher risk.

Global burden

Dry eye disease affects an estimated **5–30 %** of the world’s population, depending on diagnostic criteria, making keratitis sicca one of the most common ocular surface disorders worldwide.<sup>[2]</sup> It is a leading cause of outpatient eye visits and contributes to substantial quality‑of‑life loss and health‑care costs (≈ US $55 billion annually in the United States alone).<sup>[3]</sup>

Symptoms

Symptoms arise from tear deficiency, inflammation, and corneal epithelial breakdown. They can be intermittent or constant and may worsen in certain environments.

• Burning or stinging sensation – often described as “sand in the eye.”
• Foreign‑body sensation – feeling of grit or a splinter.
• Redness (conjunctival injection) – due to surface inflammation.
• Blurred vision – typically improves with blinking.
• Photophobia – light sensitivity, especially bright indoor lighting.
• Excessive tearing (reflex tearing) – paradoxical response to dryness.
• Eye fatigue or heaviness – especially after reading or screen use.
• Grittiness or itching – may be mistaken for allergies.
• Reduced tear meniscus height – can be visualized by an eye‑care professional.
• Corneal epithelial defects – may present as a painful spot or ulcer that does not heal.

Causes and Risk Factors

Primary mechanisms

1. Aqueous‑deficient dry eye – decreased tear production from lacrimal gland dysfunction (e.g., Sjögren’s syndrome, age‑related decline).
2. Evanescent‑mucin‑deficient dry eye – impaired lipid and mucin layers lead to rapid tear evaporation (e.g., Meibomian gland dysfunction, blepharitis).
3. Inflammatory cascade – chronic tear hyperosmolarity triggers cytokine release (IL‑1, TNF‑α) that damages corneal epithelium, perpetuating keratitis.

Risk factors

• Age > 50 years
• Female sex (estrogen influences tear production)
• Autoimmune diseases (Sjögren’s, rheumatoid arthritis, systemic lupus erythematosus)
• Contact‑lens wear (especially extended‑wear lenses)
• Medications that reduce tear output: antihistamines, β‑blockers, diuretics, isotretinoin, antidepressants
• Environmental exposures: low humidity, wind, air‑conditioning, smoke, high‑altitude
• Refractive surgery (LASIK) – can temporarily disrupt corneal nerves and tear reflexes
• Screen time > 4 hours/day – reduced blink rate

Diagnosis

Diagnosis combines a detailed history, symptom questionnaires, and objective clinical tests.

History & Symptom Scores

• Ocular Surface Disease Index (OSDI) – a 12‑item questionnaire; scores > 23 suggest moderate‑to‑severe disease.
• Review of systemic illnesses, medications, and environmental exposures.

Clinical Examination

1. Slit‑lamp biomicroscopy – evaluates tear film, conjunctiva, and corneal staining.
2. Fluorescein staining – highlights epithelial defects; a central or inferior pattern points to keratitis sicca.
3. Lissamine green or Rose Bengal staining – stains devitalized cells on the conjunctiva and cornea.

Objective Tests

• Tear Break‑Up Time (TBUT) – <10 seconds is abnormal; reflects tear film stability.
• Schirmer I test (without anesthesia) – measures basal & reflex tear production; ≤ 5 mm/5 min indicates aqueous deficiency.
• Osmolarity testing (tear osmometer) – > 308 mOsm/L supports diagnosis.
• Meibomian gland assessment – infrared imaging or manual expression to grade gland dropout.
• Inflammatory marker testing – impression cytology or confocal microscopy can reveal inflammatory cell infiltrates (used in research centers).

Treatment Options

Treatment is stepwise, aiming to restore tear film, break the inflammatory cycle, and protect the cornea.

1. Lifestyle & Environmental Modifications

• Use a humidifier (≥ 40 % relative humidity) in dry indoor settings.
• Take a 20‑second break every 20 minutes of screen work (the “20‑20‑20” rule).
• Avoid direct air flow from fans, air‑conditioners, or heaters.
• Wear wrap‑around sunglasses outdoors to reduce evaporation.

2. Artificial Tears & Lubricants

• Preservative‑free drops (e.g., Refresh Optive, Systane Ultra) – 4–6 times daily.
• Gel or ointment at night for prolonged coverage.
• Hyaluronic‑acid or carboxymethylcellulose formulations have better retention.

3. Anti‑Inflammatory Therapy

• Topical cyclosporine A 0.05 % (Restasis) or 0.1 % (Cequa) – improves tear production; onset 4–6 weeks.
• Topical corticosteroids (e.g., loteprednol 0.5 %) – short‑course for acute inflammation; monitor intra‑ocular pressure.
• Lifitegrast 5 % (Xiidra) – FDA‑approved for DED; reduces inflammatory cytokines.

4. Lipid‑Layer Restoration

• Warm compresses (5–10 minutes, 2 × daily) + lid hygiene to melt meibum.
• Omega‑3 fatty acid supplementation (1000 mg EPA/DHA daily) – modest benefit in randomized trials.<sup>[4]</sup>
• Topical lipid‑containing drops (e.g., Systane Balance).

5. Punctal Occlusion

Insertion of silicone plugs into the lacrimal puncta reduces tear drainage, increasing ocular surface moisture. Options include temporary collagen plugs or permanent silicone plugs.

6. Advanced Procedures

• Amniotic membrane transplantation – promotes epithelial healing in severe keratitis.
• Autologous serum eye drops – contain growth factors; used for refractory epithelial defects.
• Meibomian gland probing or thermal pulsation (LipiFlow) – restores gland function in obstructive MGD.
• Corneal neurotization – experimental surgery for severe neurotrophic keratitis.

Living with Keratitis sicca (ocular surface disease)

Daily Management Checklist

• Apply preservative‑free artificial tears before leaving home, after screen use, and before bedtime.
• Perform lid hygiene twice daily: warm compress → gentle massage → cleanse with diluted baby shampoo or commercial lid scrub.
• Stay hydrated (≥ 2 L water/day) and limit caffeine/alcohol, which can exacerbate dryness.
• Wear wrap‑around sunglasses outdoors and protective goggles in windy or dusty environments.
• Schedule regular follow‑up appointments (every 3–6 months) to monitor corneal staining and adjust therapy.
• Keep a symptom diary: note triggers, severity, and response to treatments; this assists the clinician in tailoring care.

Nutrition & Supplements

Omega‑3 fish oil, vitamin A (beta‑carotene), and antioxidants (vitamin C, lutein) support ocular surface health. Discuss dosages with your physician, especially if you are on blood‑thinners.

Work & Study Adjustments

Position digital screens slightly below eye level to promote a natural blink pattern, use screen filters to reduce glare, and consider “air‑clean” office spaces.

Prevention

• Identify and manage systemic diseases (e.g., control rheumatoid arthritis with DMARDs).
• Review medication list with your provider; alternate or adjust drugs that reduce tear production when possible.
• Adopt the “20‑20‑20” rule to counteract reduced blink rate during prolonged screen time.
• Maintain eyelid hygiene to prevent Meibomian gland blockage.
• Quit smoking – tobacco smoke destabilizes the tear film.
• Use protective eyewear in environments with high wind, dust, or chemical exposure.

Complications

If keratitis sicca is left untreated, the ongoing epithelial damage can lead to:

• Corneal ulceration – may progress to infectious keratitis.
• Scarring (stromal opacities) – permanent visual axis involvement.
• Neovascularization – abnormal vessels grow into the cornea, further impairing transparency.
• Reduced visual acuity – fluctuating blur can affect reading, driving, and occupational tasks.
• Secondary infections – bacterial, fungal, or viral superinfection of an epithelial defect.
• Chronic pain syndrome – neuropathic pain may persist even after ocular surface healing.

When to Seek Emergency Care

References

1. American Academy of Ophthalmology. “Dry Eye Disease.” 2023. https://www.aao.org/eye-health/diseases/dry-eye-disease
2. Mayo Clinic. “Dry eye.” Updated 2022. https://www.mayoclinic.org/diseases-conditions/dry-eye/symptoms-causes/syc-20371863
3. National Eye Institute. “Dry Eye (Keratitis Sicca).” 2021. https://nei.nih.gov/health/dryeye
4. American Journal of Clinical Nutrition. “Omega‑3 fatty acids for dry eye: a systematic review.” 2020.
5. World Health Organization. “Global burden of visual impairment 2020.” WHO Vision Report. https://www.who.int/vision/en/

```